The genomic frontier has moved. The era of "good enough" short-read data is hitting a structural ceiling, and the surge in Long-Read Sequencing (LRS) is no longer a niche academic interest—it is a competitive necessity. For organizations in clinical diagnostics, agricultural biotech, and pharmaceutical R&D, the question is no longer about the cost per base, but the cost of...